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We propose to evaluate the dissolution properties of rosuvastatin calcium (ROSC) capsules in different 
media to characterize the discriminatory power of the assay method. Dissolution assays were performed in 
media with different pH, and including the surfactant sodium dodecyl sulfate (SDS). Several immediate-
release formulations were manufactured using the commercial raw material characterized as amorphous 
solid. The hydrophobic adjutant magnesium stearate was employed in some formulations due to its 
negative effect in the wettability and dissolution efficacy of solid dosages. These formulations showed 
the lower dissolution efficacy values in media without surfactant; however, when SDS was added 
to the medium, the dissolution efficacy increased, and the discriminatory power was lost. In spite of 
micellar solubilization does not increase the ROSC solubility, it modifies the discriminatory power of 
the assay method, increasing the wettability of the powder mixtures. The crystalline form M of ROSC 
was recrystallized in our laboratory, and it showed lower solubility in water than amorphous solid. 
However, its dissolution properties were not influenced by SDS. These results are important to develop 
dissolution assays for other hydrophilic drugs with increased water solubility, once that dissolution media 
with surfactants increase the wettability of the formulations, leading to an overrated dissolution rate.
Keywords: Dissolution. Crystal polymorphism. Solid dosage form. X-ray powder diffractometry. 
Thermal analysis. Solubility.
INTRODUCTION
Rosuvastatin calcium (ROSC) (Figure 1) is a lipid-
lowering drug that competitively inhibits the enzyme 
hydroxymethylglutaryl-coenzyme A (HMG-CoA) 
reductase in the liver. HMG-CoA reductase catalyzes the 
conversion of HMG-CoA to mevalonic acid, representing 
the rate-limiting step in cholesterol biosynthesis (Alshora 
et al., 2016; Lee et al., 2014). ROSC is a hydrophilic 
statin, and Food and Drug Administration approved it 
in 2003. It was the second most prescribed drug among 
global pharmaceutical products in 2014, being primarily 
recommended to reduce plasma cholesterol levels and to 
prevent cardiovascular diseases (Lee et al., 2014; Patil-
Gadhe, Pokharkar, 2016; Sterk et al., 2016; Zhou et al., 
2013). 
The absolute oral bioavailability of ROSC is low 
(about 20%), which is mainly related to its hydrophilic 
character (log P octanol/water = 0.13) (Moffat, Osselton, 
Widdop, 2011; Balakumar et al., 2013). The hydrophillic 
statin exists as an anion at physiological pH, and it requires 
membrane transporters to be taken up into the cell, as the 
organic anion transporting polypeptides located on the 
brush-border membrane of the small intestinal enterocytes. 
ROSC is also excreted across the apical membrane of 
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the intestinal cells by efflux transporters, which also 
contributes to its limited bioavailability. Based on these 
considerations, some conventional formulations, such as 
hard gelatin capsules, are an easy and simple strategy to 
improve the drug release, increasing its availability for drug 
absorption sites in the GI tract after oral administration 
(Varma et al., 2011; Shen et al., 2015; Li et al., 2011). 
Others advantages of the capsules are the relative low 
cost of the materials and enhanced patient compliance. 
To assure the quality of these pharmaceutical dosage 
forms, dissolution assays have been performed in the 
quality control routine. However, the discrimatory power 
of these in vitro assays is an important parameter to be 
determined once the dissolution assay methods have been 
applied for delineating dosage forms, which searches for 
formulations with enhanced drug release profiles. When 
drugs with poor permeability and low bioavailability are 
evaluated, such as ROSC, its dissolution profile can be a 
tool for screening among several formulations, selecting 
those ones with improved dissolution properties (Peppas, 
Narasimhan, 2014; Qureshi, 2006). To achieve these 
goals, the dissolution testing should detect differences 
among several formulations, which can be only assured 
if the discriminatory power of the assay method was 
exhaustively studied (Matsui et al., 2016; Hoti et al., 
2008). 
In the light of these considerations, there are 
several factors affecting the dissolution properties from 
pharmaceutical dosages, which include the solid-state 
polymorphism (Snider, Addicks, Owens, 2004; Corrêa 
et al., 2016). The pharmaceutical industry manufactures 
solid dosage forms of ROSC using the amorphous solid, 
which has been reported as a solid-state form that shows 
satisfactory stability and low tendency to crystallize. On 
the other hand, several crystalline forms of ROSC have 
been described, including the crystalline forms A, B, B1, 
C, M, R, S, and TW1 (Sethi et al., 2010; Taylor, 1999; 
Sahadeva et al., 2011; Booth et al., 2009; Blatter Van 
Der Schaaf, Szelagiewicz, 2006; Nishiguch, Inakoshi, 
2013). The solid-state properties of the drug, mainly its 
solubility in water, may exert a significant effect on its in 
vitro dissolution properties from solid dosages, leading 
to different in vivo plasma profiles (Bonfilio et al., 2014).
In this study, we evaluated the discriminatory 
power of a dissolution assay for ROSC capsules. For 
this, the dissolution properties of seven formulations 
prepared with commercial raw material (amorphous 
power) were evaluated under different experimental 
conditions, including media with different pH and using 
the anionic surfactant sodium dodecyl sulfate (SDS). 
One formulation with enhanced dissolution properties 
was selected to be manufactured using the crystalline 
form M of ROSC, recrystallized and characterized 
in our laboratory. After performing these studies, the 
discriminatory power of the dissolution assay was 
evaluated under different experimental conditions, which 
demonstrated the importance of the appropriate selection 
of the experimental conditions.
EXPERIMENTAL
Chemicals, standards and reagents
All reagents were of analytical grade. The raw 
material of ROSC (assigned purity 101.43%) was acquired 
from a pharmaceutical distributor (São Paulo, São Paulo, 
Brazil), and ROSC standard (99.8%) was purchased from 
Sigma-Aldrich (St. Louis, MO, USA). Methanol for 
high performance liquid chromatography (HPLC) was 
acquired from Dinamica (Rio de Janeiro, Rio de Janeiro, 
Brazil). The hard gelatin capsules were purchased from 
Genix (São Paulo, São Paulo, Brazil). Celulomax® (Lot 
0220816) and microcrystalline cellulose (Lot 145000841) 
were purchased from Embrafarma (São Paulo, São Paulo, 
Brazil); colloidal silicon dioxide (Lot B5D23LINB6) 
was purchased from Purifarma (Anapólis, Goiás, Brazil); 
starch (Lot ALL057603) and talc (Lot ALL50556) were 
purchased from All Chemis (São Paulo, São Paulo, Brazil). 
Magnesium carbonate (Lot 16E03-B046-005423) and 
magnesium stearate (Lot 16G20-B001-008983) were 
purchased from Fagron (São Paulo, São Paulo, Brazil).
HPLC analysis
The HPLC analysis was performed using a validated 
stability-indicating assay method previously developed 
and validated in our laboratory. Samples were analyzed 
by a series LC-10A HPLC from Shimadzu (Kyoto, Japan), 
FIGURE 1 - Structure of ROSC.
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consisting of a LC-20AD pump, a CTO 20-A column 
oven, a DGU-20A degasser, a SPD-MD20A photodiode 
array (PDA) detector, a SIL-20-AC HT auto-sampler, 
and a CBM-20A controller. The chromatographic assay 
was performed at 25 °C using a Promosil (Bonna-Agela 
Technologies, Tianjin, China) reversed-phase C18 column 
150 × 4.6 mm (i.d.) with particles of 5 μm. The mobile 
phase was a mixture of methanol and water with pH 
adjusted to 3.0 using phosphoric acid (65:35, v/v). The 
flow rate of mobile phase was 1.0 mL min−1, the injection 
volume was 20 µL, and UV detection was performed 
at 241 nm. The UV spectrum in the range of 200–400 
nm was evaluated to determine the similarity index of 
ROSC peaks in the selectivity studies. The samples were 
filtered using a 0.45 µm syringe filter of hydrophilic 
polytetrafluoroethylene (PTFE) (Millipore, Bedford, 
Massachusetts, USA). The retention time of ROSC was 
approximately 4.5 min. The run time was 10 minutes.
Preparation of crystalline form M of ROSC
To prepare the crystalline form M of ROSC, the 
commercial raw material (1.5 g) was dissolved in 30 mL 
of a solution composed by acetonitrile and water (1:1, 
v/v). The preparation was based on the method previously 
proposed by Sahadeva and co-workers (Sahadeva et al., 
2011). The solution was previously heated to 50 ± 1 °C 
until complete dissolution of ROSC, and after, the solution 
was cooled at 15 ± 1 °C. Following, the solution was 
stirred (150 rpm) at room temperature (25 ± 1 °C) in an 
open erlenmeyer flask. After this time, it was observed a 
considerable amount of particles dispersed in the solvent. 
The content of the flask was filtered through a 0.45 
µm PTFE membrane, and the crystalline powder was 
recovered on the membrane surface. The powder was left 
to dry in an oven at 50 °C for 12 hours, and it was further 
characterized using different techniques.
Characterization of the solid-state forms 
The assay of ROSC in the raw material before and 
after recrystallization in our laboratory was performed 
by the HPLC assay method using the chromatographic 
conditions previously described (n = 3). For this, solutions 
of the drug at 20 µg mL−1 concentration were diluted 
using a mixture of methanol and water (65:35, v/v) before 
injection into the chromatographic system (20 µL).
The diffraction pattern of ROSC was analyzed by 
X-ray powder diffractometry (XRPD) using an equipment 
model Rigaku Ultima IV (type II) (Tokyo, Japan). The 
PXRD measurements were carried out at room temperature 
under the following conditions: graphite monochromatic 
Cu-Kα radiation (γ = 1.542˚A), voltage of 40 kV, current 
of 30 mA, and a scan rate of 1°/min between 3° and 30° 
of the 2θ range. 
Infrared spectra were measured with a Shimadzu 
IR Affinity-1 Fourier transform infrared (FTIR) 
spectrophotometer (Shimadzu, Tokyo, Japan) equipped 
with Attenuated Total Reflection (ATR) sampling 
accessories Pike Miracle® with zinc selenide (ZnSe) 
crystals Pike Technologies® (Madison, Wisconsin, USA). 
The FTIR spectra were recorded at room temperature in 
the 4,000–600 cm−1 range. After recording a background 
spectrum, the samples were placed on the ZnSe crystal. 
Thermal analysis was carried out using differential 
scanning calorimetry (DSC) and thermogravimetric 
analysis (TG). The DSC analysis was performed using a 
Netzsch-Gerätebau GmbH instrument model DSC 3500 
Sirius (Selb, Germany). DSC curves were obtained at a 
heating rate of 10 °C min−1 from 30 °C to 300 °C under a 
N2 purge of 50 mL min−1 (n = 3). TG was performed using 
an Exstar TG/DTA-7300 thermogravimetric analyser 
(Chiba, Japan). TG curves were obtained at a heating rate 
of 10 °C min−1 from 30 °C to 300 °C under a N2 purge of 
50 mL min−1.
The equilibrium solubility of ROSC (amorphous 
solid-state and crystalline form M) was evaluated by 
the shake-flask method in different aqueous media. The 
following aqueous media were evaluated: 0.1 mol L−1 
HCl (pH 1.2), pure water, sodium acetate buffer (pH 
4.5), sodium acetate buffer (pH 4.5) + SDS 0.1% (w/v), 
and potassium phosphate buffer (pH 6.8). To determine 
the equilibrium solubility, an excess of the drug was 
added to 1 mL of the aqueous medium, and the solutions 
were stirred at 150 rpm for 24 h at 37 ± 1 °C (n = 3). The 
saturated solutions at equilibrium were filtered using 
a 0.45 µm syringe filter of PTFE. Thus, the solutions 
were successively diluted in mobile phase (pH 3.0), and 
analyzed by the HPLC method.
Formulations
The mixture of powders (ROSC and excipients) 
were encapsulated in hard size four gelatin capsules 
(n = 120). The formulations containing 20.84 mg of ROSC 
(corresponding to 20 mg of free base) are described in 
Table I. All formulations were manufactured with ROSC at 
amorphous solid-state, with the exception of formulation 
D that was prepared with the crystalline form M. The raw 
materials (amorphous solid-state and crystalline form M) 
were previously ground and sieved in order to standardize 
their particle size (75–106 µm). The set of formulation 
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was selected based on the effect of the excipients on 
the dissolution properties of the active pharmaceutical 
ingredient, mainly the negative effect of magnesium 
stearate, and the positive effect of Celulomax E®, which 
contains croscarmellose sodium.
These formulations showed satisfactory results for 
uniformity content and assay of ROSC, with the results 
within in the range of 95%–105%.
DISSOLUTION ASSAYS
The dissolution profile of ROSC from capsules was 
performed at 37.0 ± 0.5 °C using different experimental 
conditions. The assays were performed in an Electrolab 
TDT–08L multi bath (n = 8) dissolution test system 
(Mumbai, Maharashtra, India) equipped with USP I 
apparatus (basket) and USP II apparatus (paddle) in 
accordance with USP General Chapters (USP, 2015).
The dissolution media (500 mL) evaluated were 
sodium acetate buffer (pH 4.5), sodium acetate buffer (pH 
4.5) + 0.1% (w/v) SDS, and potassium phosphate buffer (pH 
6.8). The experimental apparatus tested were basket (USP 
I apparatus) and paddle (USP II apparatus) using stainless 
steel sinkers (CAPWST-18, 18.0 x 6.0 mm, SMI-Labhut 
Ltd., UK) to avoid the floating of the capsules. The stirring 
speeds of 50 and 100 rpm were studied. The samples (5 mL) 
were withdrawn at several times, and they were immediately 
replaced with equal volume of the dissolution medium. 
The samples were filtered using quantitative paper filters 
(Quanty, Germany) and diluted (1:1, v/v) with mobile phase 
(pH 3.0). Drug quantification was performed by the HPLC 
method. The dissolution profiles of the ROSC capsules were 
compared by calculating the dissolution efficacy (DE%), 
which was calculated as the percentage of the area under 
the release curve.
Validation studies 
The dissolution assay method for evaluation of 
ROSC in gelatin capsules was validated in accordance 
with the recommendations of the ICH Q2B guidance 
(ICH, 1995). For this, standard stock standard solutions 
of ROSC at 1,000 μg mL−1 were diluted in pure methanol. 
The intermediate solutions at 100 μg mL−1 were diluted 
in potassium phosphate buffer (pH 6.8) (dissolution 
medium). The working solutions were prepared diluting 
the intermediate solution with the dissolution medium. 
The dissolution assay was validated in the following 
experimental conditions: 500 mL of phosphate buffer (pH 
6.8) at 37.0 ± 0.5 ºC using USP I apparatus at 100 rpm. The 
formulation E was selected for validation studies. 
The selectivity of the dissolution assay method was 
determined by evaluating the solutions of the placebo, 
standard solutions of ROSC at concentration of 20 μg 
mL−1, and sample solutions of the powder mixture of the 
capsules diluted at this same concentration. The peak 
purity of the samples was analyzed using a PDA detector 
for determining the similarity index. Linearity (n = 3) 
was determined by analysis of ROSC standard solutions 
at five concentration levels (5, 10, 15, 20, and 25 mg L−1). 
The dilutions were prepared on three different days (n 
= 3). The correlation coefficient (r) and the calibration 
equation (y = ax + b) were calculated, where a corresponds 
to the slope and b is the linear coefficient (intercept). The 
limit of detection (LOD) and limit of quantitation (LOQ) 
were calculated from the calibration equation using the 
following equations:
  (Equation 1)
TABLE I - Composition of the ROSC formulations
Components
(%)
A B C Db E F G H
Colloidal silicon dioxide 1.0 2.5 - 2.5 2.5 2.5 2.5 2.5
Talc 5.0 7.5 - 7.5 7.5 7.5 7.5 7.5
Starch 74.0 81.5 - 80.0 80.0 90.0 87.5 85.0
Magnesium stearate - 1.0 - - - - 2.5 5.0
Magnesium carbonate 10.0 7.5 - 10.0 10.0 - - -
Microcrystalline cellulose 10.0 - - - - - - -
Celulomax E®,a - - 100.0 - - - - -
aCommercial powder mixture composed by microcrystalline cellulose, colloidal silicon dioxide, stearic acid, and croscarmellose 
sodium (superdisintegrant); bManufactured with the crystalline form M of ROSC.
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  (Equation 2)
where SD is the standard deviation of the intercept, and a 
is the slope of the calibration equation. 
The intraday and interday precision (n = 6) of 
the dissolution assay method were determined by the 
amount of drug dissolved at 30 minutes (Q30 min), and 
expressed as relative standard deviation (RSD) according 
to equation 3:
 (Equation 3)
The accuracy was evaluated by adding known 
amounts of ROSC standard substance to the placebo 
mixture of formulation E once the formulation exhibited 
enhanced dissolution properties. A standard stock solution 
containing 5 mg mL−1 of ROSC standard substance was 
prepared in the mobile phase, and aliquots of 3, 4, and 
5 mL of standard stock solution were added to vessels 
with dissolution medium for a total volume of 500 mL, 
achieving the final concentrations of 30.0, 40.0, and 50.0 
μg mL−1 (n=3). The solutions were diluted (1:1, v/v) in the 
same way that samples of the dissolution test using the 
mobile phase (pH 3.0). These concentrations correspond to 
75%, 100%, and 125% of the final concentration. Aliquots 
were withdrawn at 30 minutes, and samples were analyzed 
by the HPLC method. The recovery percentage (RE, %) 
was calculated according to Equation 4.
  (Equation 4)
RESULTS AND DISCUSSION
The amorphous state does not have a three-
dimensional long-range order as crystalline materials. 
While the crystalline state is thermodynamically favored 
for solids, which is characterized by its three-dimensional 
order of the molecules within the crystal lattice, the 
amorphous state has been characterized by the random 
conformation of the molecules. As a result, amorphous 
state is thermodynamically unstable and may convert to 
a stable crystalline state. However, this entropic process 
of conversion may be slow, and more stable amorphous 
forms are sometimes isolated and used to produce 
pharmaceutical dosage forms. In this case, the active 
pharmaceutical ingredient at amorphous state may have 
higher solubility than corresponding crystals, also showing 
increased dissolution rates and better compression 
characteristics. However, it may be less stable chemically 
and physically than their crystalline forms (Cruz-Cabeza, 
Reutzel-Edensb, Bernsteincd, 2015).
The commercial raw material of ROSC was 
characterized as an amorphous powder using thermal 
analysis (Figure 2A) and XRPD (Figure 3). The amorphous 
solid was characterized by the absent of peaks in the 
X-ray diffractogram (Figure 3), and at same time by the 
absence of a well-defined thermal event corresponding 
to the melting point in the DSC curve (Figure 2A). For 
the amorphous powder, the DSC curve exhibited an 
endothermic thermal event from 50 °C up to 100 °C, 
representing the water losses from the raw material. 
The mass losses were determined by TG (3.7% at 100 
°C). The second endothermic event is not a well-defined 
peak in the DSC curve, and it was associated with the 
melting of the amorphous solid, which was confirmed by 
visual analysis using capillary tubes and a melting point 
apparatus, indicating a range of values around 152–161 
°C. The third and final thermal event in the DSC curve of 
the amorphous powder corresponds to thermal degradation 
of ROSC, occurring at an increased rate from 158 °C. 
Thermal degradation of ROSC was confirmed by mass 
losses using TG. 
The crystalline form M was prepared in our 
laboratory, and characterized by the XRPD, indicating 
peaks at 3.29, 5.28, 6.80, 7.50, 9.30, 10.34, 11.72, 13.14, 
17.64, 18.67, 20.41, 22.17, and 22.48 of the 2θ range 
(Figure 3). These peaks has the same position to those 
observed in form M, which was first characterized by 
Sahadeva and co-workers (Sahadeva et al., 2011), allowing 
the identification of this crystalline structure. The DSC 
curve of this crystalline structure (Figure 2B) exhibited 
an initial endothermic peak at 68 °C, corresponding to 
solvent losses, which was confirmed by TG (2.6 %). 
The second endothermic thermal event from DSC curve 
appears around 103 °C, corresponding to a temperature-
mediated solid-state transformation. The melting point 
of crystalline form M was a well-defined endothermic 
peak at 176 °C, and it was confirmed by visual analysis 
using capillary tubes and a melting point apparatus (> 
168 °C). Following, thermal degradation of ROSC from 
the crystalline structure started at 190 °C, being clearly 
observed by TG. To confirm the temperature-mediated 
solid-state transformation, the crystalline form M was 
heated up to 105 °C for 2h, and DSC and XRPD analysis 
were performed. These results were not previously 
reported, and the peaks from the crystalline form M after 
heating were observed at 3.38, 5.40, 6.80, 10.46, 13.19, 
17.55, 19.03, 21.44, and 22.69 of the 2θ range (Figure 3). 
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The DSC of crystalline form M after heating did not 
indicate a endothermic thermal event around 100 °C, 
which was previously observed in figure 2B; however, a 
well-defined endothermic peak was observed at 175 °C, 
which was related to its melting point (Data not shown).
The ATR-FTIR spectra (Figure 4) of the ROSC 
(crystalline form M and amorphous solid-state) allowed 
the identification of the functional moieties in its chemical 
structure. The infrared stretching frequencies observed 
were aromatic v = 1,540.7 cm−1 (C=C), v = 1,436.9 cm−1 
(C-H), v = 1,379.1 cm−1 (O=S=O), v = 1,151.5 cm−1 (C-O), 
and aromatic v = 775.9 cm−1 (C-H).
The assay of ROSC in raw material was performed 
by HPLC method, and indicated a value of 99.83% ± 
0.44% for amorphous solid and 99.94% ± 0.37% for the 
crystalline form M. 
The HPLC method for analysis of ROSC in 
dissolution medium (using phosphate buffer pH 6.8 as 
diluent) was validated using a mixture of mobile phase 
(pH 3.0) as a sample diluent. The calibration equation 
and correlation coefficient (r) were y = 49,091 (±465) x 
+ 25,595 (±1,247) and 0.999688, respectively. The drug 
response was linear over the concentration range of 1 to 
25 µg mL−1. The LOQ and LOD were calculated, and 
the values found were 0.35 µg mL−1 and 0.12 µg mL−1, 
respectively. Results for accuracy and precision of 
analytical method were considered satisfactory, and they 
were shown in Table II. The criteria adopted for precision 
and recovery were the same employed for the assay of raw 
material and for capsule dosage form.
The equilibrium solubility of ROSC showed a 
pH dependent behavior related to the ionization of 
the carboxylic acid moiety (pKa = 4.6) at higher pH 
values (Figure 5). The solubility of amorphous solid 
was larger than the crystalline structure in the media 
evaluated, which is relative to enhanced thermodynamic 
properties (e.g., solubility) of amorphous state due to 
its higher internal energy. The solubility of ROSC in 
media with acid pH values showed minor differences 
between amorphous solid and the crystalline structure. 
The amorphous powder showed a solubility of 0.53 ± 
0.01 mg mL−1 in 0.1 mol L−1 HCl against 0.42 ± 0.06 mg 
mL−1 for crystalline form M. The solubility of ROSC in 
medium sodium acetate buffer (pH 4.5) was determined 
with and without the addition of anionic surfactant SDS 
at 0.1% w/v. The results obtained in the medium sodium 
acetate buffer (pH 4.5) without SDS were 2.42 ± 0.09 
mg mL−1 for amorphous solid, and 2.00 ± 0.01 mg mL−1 
for crystalline form M. When the SDS was added to 
medium sodium acetate buffer (pH 4.5), the solubility 
values were 2.21 ± 0.04 mg mL−1 for amorphous powder, 
and 2.14 ± 0.03 mg mL−1 for crystalline form M. From 
these results, it was demonstrated that solubility of 
ROSC did not improve by the addition of surfactant 
in the medium, indicating that micellar solubilization 
of the hydrophilic drug was not an efficient strategy to 
increase its solubility. The differences in the equilibrium 
solubility of the amorphous solid was better evidenced 
in phosphate buffer pH 6.8 (14.34 ± 1.86 mg mL−1 for 
amorphous solid, and 5.73 ± 0.66 mg mL−1 for the 
crystalline form M) and water (7.64 ± 0.24 mg mL−1 
for amorphous solid, and 4.13 ± 0.58 mg mL−1 for the 
crystalline form M). After the solubility measurements, 
the solid precipitate were characterized using XRPD, 
and the results indicated a solution-mediated phase 
transformation from the crystalline form M of the 
ROSC to the amorphous solid. The major peaks of the 
crystalline structure were still observed in the X-ray 
diffractogram of the precipitate after 24 h, but with a 
very low intensity (Data not shown). These results are 
counterintuitive, once that solids at amorphous state has 
higher free energy than their corresponding crystals. In 
FIGURE 2 - DSC and TG curves of ROSC: A) Amorphous powder; B) Crystalline form M.
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this way, the hypothetical explanation for this solution-
mediated transformation may associate with crystal 
M, once this crystalline structure is not spontaneously 
obtained at room temperature, being necessary to heat 
the ROSC solution in acetonitrile and water, 1:1 v/v until 
50 °C, and after cooling the drug solution at 15 °C to 
induce its precipitation. During the equilibrium solubility 
measurements, the assays were carried out at 37 °C, and 
at these conditions, the soluble drug precipitated as an 
amorphous powder instead of this crystalline structure, 
which must be associated with a more stable amorphous 
state of ROSC. The evidence that crystalline form M has 
a temperature-mediated solid-state transformation when 
it is heated until 105° C may also support these results, 
demonstrating that some crystalline structures of this 
drug are only obtained under heating. Considering the 
pH dependent behavior of ROSC, which is related to its 
ionization at higher values of pH, the large solubility of 
amorphous powder at pH 6.8 may be associated with 
combined factors acting together as drug ionization and 
FIGURE 3 - XRDP of ROSC: amorphous solid-state; crystalline 
form M, and its phase transition after heating to 105 °C for 2h.









75 98.76 ± 0.37
97.94 ± 1.62 98.99 ± 1.41 100 100.7 ± 0.11
125 99.95 ± 0.86
aQ30min, amount of drug released at 30 minutes (formulation E); 
bSD, Standard deviation.
FIGURE 4 - IR spectra of ROSC in amorphous solid-state and 
crystalline form M.
M. L. Ângelo, A. L. M. Ruela, A. C. M. Ferreira, M. V. F. Ramos, C. M. Montanari, L. M. Silva, M. B. Araújo
Braz. J. Pharm. Sci. 2019;55:e17520Page 8 / 11
the solution-mediated transformation of form M into 
amorphous powder, resulting in an enhanced solubility 
of ROSC at higher pH values.
The solubility studies demonstrated that sink 
conditions were achieved in each medium evaluated for 
both crystalline form M and amorphous solid. The criteria 
adopted for sink conditions was to obtain a saturated 
solution of drug in the aqueous media with a concentration 
at least three times higher than the drug concentration 
determined at the end of dissolution testing. When the 
method assures sink conditions, the drug solubility in 
the dissolution medium is not a limiting factor for its 
dissolution rate. Due to the occurrence of sink conditions 
in vivo, the biological relevance of these dissolution media 
is improved (Cardot, Beyssac, Alric, 2007; Bonfilio et al., 
2012). Thus, ROSC was soluble in the evaluated aqueous 
media, assuring sink conditions in a broad pH range (1.2 
to 6.8). According to Biopharmaceutical Classification 
System, this drug is highly soluble; its major tablet dosage 
is 40 mg, and this amount of drug can be easily dissolved 
in 250 mL of the aqueous media in the pH range from 
1.2 to 6.8 (solubility > 0.16 mg mL−1). Considering that 
ROSC formulations are usually manufactured using the 
amorphous powder, this salt must be classified as a class 
III drug, which was already previously reported (Peng et 
al., 2009).
The formulations described in Table I were evaluated 
under several experimental conditions in order to select 
a dissolution test for evaluating ROSC capsules with 
increased discriminatory power. Based on this, the ROSC 
formulations must provide an immediate-release profile, 
improving the drug availability for absorption on GI tract. 
The DE% was selected as a satisfactory parameter to 
compare the dissolution properties from the formulation 
set (Figure 6). The formulations were firstly evaluated at 
50 rpm in the medium potassium phosphate buffer pH 
6.8 due to the increased drug solubility at this pH value 
(Figure 6A). All formulations were evaluated using USP I 
apparatus (basket); this experimental apparatus is usually 
employed for evaluating capsules, avoiding its fluctuation. 
However, formulations codified as C-2 and G-2 were also 
evaluated using USP apparatus II (paddle). The results 
indicated that the experimental apparatus at 50 rpm showed 
a minor effect on the dissolution properties of ROSC 
capsules in the medium potassium phosphate buffer pH 6.8 
(p > 0.05, Student t-test). The formulation C containing a 
superdisintegrant agent (sodium croscarmellose) showed 
high values of DE% (> 50%) according to expected, 
while the formulation G containing 2.5% of magnesium 
stearate showed low values of DE% (< 20%). The negative 
effect of magnesium stearate in the DE% is well known. 
This hydrophobic pharmaceutical adjutant can decrease 
the wettability of the formulations with the dissolution 
medium and, consequently, their dissolution rates. The 
FIGURE 6 - Dissolution efficacy (%) of ROSC capsules (n=6).
FIGURE 5 - Solubility of ROSC in aqueous media at 37°C (n=3).
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DE% values were decreased when magnesium stearate 
concentration was increased as observed from the results 
obtained with formulations B (36.1% ± 9.9%), G (17.7% 
± 2.6%), and H (3.5% ± 0.4%), containing respectively, 
1%, 2.5%, and 5% of magnesium stearate.
The formulation D and E contain the same 
composition of excipients;  however,  they were 
manufactured with different solid forms of ROSC. The 
formulation D was prepared using crystalline form M, and 
its DE% value was 27.1% ± 1.9%, while the amorphous 
solid (formulation E) exhibited a DE% value of 58.6% ± 
3.6%. These results were associated with the increased 
solubility coefficients of the amorphous powder, increasing 
the dissolution rate of ROSC from formulation E.
The ROSC capsules were evaluated at different 
media at 100 rpm (acetate buffer pH 4.5 with or without 
SDS, and phosphate buffer pH 6.8) using USP apparatus 
I (Figure 6B). The results obtained using USP apparatus 
II for formulation A, B, and C in three different media 
(acetate buffer pH 4.5 without SDS, acetate buffer pH 4.5 
with SDS, and phosphate buffer pH 6.8) were similar to 
those using USP apparatus I, indicating a minor effect of 
the experimental apparatus at 100 rpm on the dissolution 
properties of ROSC capsules (Data not shown; p > 0.05, 
Tukey post-hoc test). The results indicated that aqueous 
media had a major effect on dissolution properties from 
formulation B (contains 1% of magnesium stearate) in 
comparison with formulations A and C. The formulation 
A showed enhanced dissolution properties as compared 
to C, E, and F. The formulation B showed a minor DE% 
in the medium acetate buffer pH 4.5 without SDS (21.4% 
± 1.9%), and a major DE% in the medium acetate buffer 
pH 4.5 with SDS (68.1% ± 9.0%). Besides the ROSC 
has a similar solubility in acetate buffer pH 4.5 with or 
without SDS, the results demonstrated that the presence of 
SDS increased the DE% of formulation B; the surfactant 
increased the wettability of this formulation. From these 
results, the medium acetate buffer pH 4.5 with SDS was 
not considered a promising dissolution medium for ROSC 
capsules, showing low discriminatory power (Figure 7A). 
DE% of formulation B in medium phosphate buffer pH 
6.8 was 41.5 ± 8.0%, and this increased value of DE% of 
formulation B in medium phosphate buffer pH 6.8 was 
41.5% ± 8.0%, and this increased value of DE% was 
related to the major drug solubility in this experimental 
condition. The medium phosphate buffer pH 6.8 also 
showed a considerable discriminatory power between the 
formulations with or without magnesium stearate. The 
capsule formulation prepared with the crystalline form 
M (formulation D) was also evaluated in medium acetate 
buffer pH 4.5 with SDS and phosphate buffer pH 6.8 at 100 
rpm, showing DE% values of 49.9% ± 7.8% and 56.1% 
± 11.2%, respectively. According to these results, the 
formulation D exhibited very similar dissolution profiles 
(Figure 7B) in both media, being able to discriminate 
between the different solid-state forms of the ROSC. 
In this way, the medium phosphate buffer pH 6.8 was 
selected considering the major drug solubility, and its 
discriminating power for evaluating ROSC capsules was 
satisfactory using USP apparatus I at 100 rpm.
CONCLUSIONS
Based on our results, we suggest that dissolution 
properties of hydrophilic drugs with high solubility in 
water may be overrated in dissolution media including 
surfactant. This phenomenon occurs due to the improved 
wettability of the formulations in the presence of 
surfactant, leading to an increased dissolution rate of 
the hydrophilic drugs and loss of discriminatory power 
among the formulations. On the other hand, dissolution 
media with surfactants were able to discriminate between 
FIGURE 7 - Dissolution profiles of ROSC capsules from different media using basket at 100 rpm (n=6).
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the amorphous powder and crystalline form M of ROSC, 
once that the surfactant SDS did not increase its solubility. 
In this way, the selected conditions to perform dissolution 
testing of ROSC capsules were 500 mL of potassium 
phosphate buffer (pH 6.8) using basket apparatus at 100 
rpm. The specification of 85% of drug dissolved at 30 
minutes was recommended as single-point specification 
for the routine analysis of quality control of ROSC 
capsules.
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